Trial | NCT00823602  Report issue

Title

Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    2
Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients. Up to now, however not enough prospectives have been published to prove any beneficial effect of antagonists on the first cycle assisted reproductive technique.

This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.

The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .
Study Started
Mar 31
2008
Primary Completion
Oct 31
2008
Study Completion
Jan 31
2009
Anticipated
Last Update
Jan 15
2009
Estimate

Drug ganirelix

These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).

Drug suprefact

GnRH agonist, standard protocol

1 Experimental

GnRH antagonist "ganirelix" 0.25 mg fromm 6th ovarian stimulation

2 Active Comparator

GnRH agonist, suprefact, stimulation with a standard long protocol

Criteria 

Inclusion Criteria:

first cycle of ART
age < 35 years
basal FSH < 10 IU/L

Exclusion Criteria:

previous IVF or ICSI, hyperprolactinemia, hyperthyroidism, hypothyroidism, uterine abnormality, severe endometriosis
only one ovary
No Results Posted